Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

oduct liability, supply, competition and other risks).

-more-

(Financial Table Attached)

ENTREMED, INC.

SUMMARY OF OPERATING RESULTS

Three Months Ended

September 30,

2008 2007

Total revenues $3,501,307 $3,520,259

Research and development 4,957,067 5,109,257

General and administrative 1,551,900 1,706,451

Acquired in-process research and development 0 0

Net Loss (3,397,877) (3,035,346)

Net Loss per share (basic and diluted)

attributable to common shareholders $(0.04) $(0.04)

Weighted average number of shares

outstanding (basic and diluted) 87,728,644 84,223,912

Nine Months Ended

September 30,

2008 2007

Total revenues $3,501,307 $3,520,259

Research and development 16,629,127 18,089,240

General and administrative 5,274,585 5,407,588

Acquired in-process research and development 2,000,000 0

Net Loss (21,314,476) (18,643,625)

Net Loss per share (basic)

attributable to common shareholders $(0.26) $(0.23)

Weighted average number of shares

outstanding (basic) 86,060,438 84,015,999

Ca
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), is pleased to announce that Biohaven Pharmaceutical ... equity, has entered into an agreement with inVentiv ... clinical trial with their lead compound (BHV-0223). ... and development of clinical stage neuroscience compounds targeting ...
(Date:4/1/2015)... , April 1, 2014 /CNW/ - Canada,s ... Review Board,s (PMPRB) newly released report on Cost Drivers of ... notes that, according to the report, the rates of change ... reaching a low of -0.8 percent in 2012/13 for a ... any study that examines the costs of medicines without considering ...
(Date:4/1/2015)... Angeles, CA (PRWEB) April 01, 2015 ... reader that can read both chromatographic and fluorescent rapid ... leading supplier of high performance, quantitative readers and is ... globally. The HRDR-400 is a first of its kind ... in one instrument. , Dr. Neven Karlovac, CEO ...
(Date:4/1/2015)... recruitment firm Slone Partners is pleased to ... Sales at Optimal Medicine, an international digital health group ... over 20 years experience in healthcare information technology client ... Dell Services Healthcare, Medsphere Systems and McKesson. , ... accomplishing the goals Optimal Medicine had for this role,” ...
Breaking Biology Technology:Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2Slone Partners Fills Head of Sales at Optimal Medicine 2
... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... banking operator in China, today announced the completion of ... holders to receive one ordinary share for every eight ... to 2.2% of shares outstanding as of December 10, ...
... Research Group, Inc. finds that with the introduction of Novartis, ... of multiple sclerosis (MS), neurologists anticipate major shifts in the ... of Gilenya, trial and uptake of Extavia, a DMA launched ... to the perception that Extavia is a "me too" agent ...
... 2010 Scientists from Pacific Biosciences of California, Inc. ... single molecule, real-time (SMRT) DNA sequencing technology to rapidly ... epidemic in Haiti. Published Thursday in the ... the first whole genome sequence analysis and most detailed ...
Cached Biology Technology:China Cord Blood Corporation Announces Completion of Warrant Exchange 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 2Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 3
(Date:4/1/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces the second shipment of ... to early access pre-order customers. Feedback ... outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop & ... at all outlets and very easy to use. Several ...
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... declining worldwide, and their declines far exceed those of ... are listed as threatened according to the Red List ... (IUCN). Multiple factors threaten global amphibian diversity but the ... poorly known. A new study published in Nature ...
... Physical activity will definitely lower children,s chances of developing ... not necessarily increase it. Findings from a recent Queen,s ... have different consequences for young people,s health. "Even ... really only making up a short period of their ...
... we regret, buy things we really don,t need, engage in ... are different kinds of hastiness and rashness embedded in our ... yes -- especially if you,re a man. The ... Scott Stoltenberg, found links between impulsivity and a rarely researched ...
Cached Biology News:Predicting future threats for global amphibian biodiversity 2Study IDs new genetic links to impulsivity, alcohol problems in men 2
... for all tested applications). ... from within residues 1 - 100 of Mouse ... proprietary) (Peptide available as ... 5453 Swiss Protein ID: ...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
Biology Products: